Mankind Pharma

Mankind Pharma Dividend Yield

The Dividend Yield of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 0.05 %.

Dividend Yield

0.05 %

Last updated:

Dividend Yield of Mankind Pharma is 2025 0.05 % . Dividend Yield of Mankind Pharma was 2024 - . It decreases by % lower compared to the previous year.

The Mankind Pharma Dividend Yield history

The Mankind Pharma Dividend Yield history
YEARDividend YieldYoY
0.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mankind Pharma stock

Dividend Yield of Mankind Pharma is 0.05 % in 2025.

On Eulerpool you can find the complete historical development of Dividend Yield Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

Dividend yield measures the annual dividend payment relative to the stock price. It shows the return an investor receives from dividends alone.

Dividend Yield's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Yield's Mankind Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Mankind Pharma

All Key Metrics — Mankind Pharma